Digitalisation of health records leveraging RWE

“It’s getting more expensive to do traditional clinical trial research, so industry is looking at ways it can achieve similar goals using routinely collected data,” said Paul Taylor, a health informatics expert at University College London. “As the breadth and reliability of RWE increases, so do opportunities for FDA to also make use of this […]

Read More

European regulators are looking at RWE for HTA

Two ongoing Horizon 2020 projects, COMED and IMPACT-HTA, will provide methodological guidance on how to use RWD for health economic evaluation, where COMED will be focusing more on medical devices and IMPACT-HTA on economic evaluation in the context of HTA Click here to see the source material Reference Comedh2020.eu. (2019). Home. [online] Available at: http://www.comedh2020.eu/wps/wcm/connect/Site/COMED/Home [Accessed 5 Mar. 2019]. […]

Read More

50% of real-world studies started in the last 3 years

Half of the world’s 1,800 clinical studies involving real-world or real-life data since 2006 have been started in the last three years (from 2015-2018), according to a Reuters analysis of the U.S. National Institutes of Health’s clinicaltrials.gov website Studying real-world evidence offers manufacturers a powerful tool to prove the value of their drug Hot areas […]

Read More
002 FINAL SVMPharma RWE highlight infographic 03-01-2019

RWE roundup – December 2018

FDA FDA releases new strategic framework for assessing the potential use of RWE in connection with drug review program Click here to find out more   ASH Researchers identify nutation in BCL2 protein that causes resistance to venetoclax in progressive CLL Click here to find out more   NICE NICE recommends MSD’s Keytruda within the CDF […]

Read More

Unique real-world study in diabetic macular oedema (DMO)

SVMPharma has recently collected real-world data in the UK (ICE-UK) and Portugal (ICE-PT) for DMO patients looking at the effectiveness of fluocinolone acetonide intravitreal implant (LUVIEN®). This has led to successful outcomes leading to multiple publications to presentations in a major European congress in 2017 and 2018 Chart notes Treatment data Align with KOLs SVMPharma’s […]

Read More

DESERVE showed significant benefits in NHS healthcare savings

SVMPharma’s real-world evidence helped deliver a real-world study looking at the clinical outcomes of triptorelin vs other LHRH agonists (LHRHa) in clinical practice for prostate cancer patients. Our real-world evidence helped show a significant reduction in healthcare resource utilisation for the NHS as well as maintenance in PSA control (a biomarker in prostate cancer) when switching to a 6-monthly formulation […]

Read More
FINAL RWE38 ICE-PT

A retrospective cohort study of the clinical outcomes of ILUVIEN in four ophthalmology centres in Portugal (ICEPT)

SVMPharma’s real-world evidence helped deliver a unique real-world multicentre study in Portugal (ICEPT) looking at the clinical outcomes of fluocinolone acetonide implant (ILUVIEN®) in clinical practice for diabetic macular oedema (DMO) patients. Our real-world evidence provided valuable insights and helped show a marked reduction in odema in 66% of DMO patients’ eyes (n=75) in real-world clinical practice.   A retrospective cohort study […]

Read More
FINAL RWE36 ICE infographic

SVMPharma’s real-world studies in diabetic eye oedema led to multiple successful publications and congress presentations in the UK and Europe

SVMPharma has recently collected real-world data in the UK and Europe for which has lead to successful outcomes from publications to presentations in a major European congress Click on the references below to find out more References (1) Currie CJ. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular […]

Read More
FINAL RWE37 CF infographic

First real-world multicentre study of the use of inhaled aztreonam lysine in clinical practice

SVMPharma’s Real World Treatment Evaluator tool helped deliver the first real-world multicentre study of the use of inhaled aztreonam lysine in clinical practice for cystic fibrosis (CF) patients. Our treatment evaluator tool provided valuable insights and demonstrated significant improvement in lung function in CF patients in a real-world setting.   A treatment evaluator tool to monitor the […]

Read More